Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

British stocks had a mixed finish on Friday due to a stronger sterling and losses in the pharma sector. While the FTSE 100 ...

Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...

In this process, royalty recipients often face the issue where multiple small future royalty streams cannot fulfill ongoing large lump-sum R&D funding needs. The mismatch is where Royalty Pharma ...

The S&P 500 advanced 1.0% on Thursday, Feb. 13, as an executive order deferred the possible implementation of reciprocal ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Corbus Pharmaceuticals (CRBP – Research ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Apellis Pharmaceuticals (APLS – Research ...

U.S. stocks are sinking after a report said inflation is unexpectedly getting worse for Americans. The S&P 500 fell 0.9% in ...

Royalty Pharma is giving Biogen $250 million for its lupus treatment litifilimab, which is currently in Phase 3 development ...